Removing the black box warning for depot medroxyprogesterone acetate

Contraception

Volumn 84, Issue 3, 2011, Pages 212-213

  Kaunitz, Andrew M ^a   Grimes, David A ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Black box; Bone mineral density; Depot medroxyprogesterone; Skeletal health

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE;

BLACK BOX WARNING; BONE DENSITY; BONE FRAGILITY; BONE MASS; BREAST FEEDING; CASE CONTROL STUDY; DRUG INFORMATION; DRUG LABELING; ENDOCRINE DISEASE; FRAGILITY FRACTURE; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HUMAN; HYPOESTROGENISM; LONG TERM CARE; NOTE; POSTMENOPAUSE; PRESCRIPTION; PUBLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; WOMEN'S HEALTH;

BONE DENSITY; CONTRACEPTIVE AGENTS, FEMALE; DRUG LABELING; DRUG UTILIZATION; FEMALE; FRACTURES, BONE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MEDROXYPROGESTERONE ACETATE; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PREGNANCY; PRESCRIPTIONS;

EID: 80051870278     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.01.009     Document Type: Note

References (21)

1. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception Arch Pediatr Adolesc Med 159 2005 139 144 (Pubitemid 40194179)
2. Harel Z., Johnson C.C., and Gold M.A. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections Contraception 81 2010 281 291
3. Scholes D., LaCroix A.Z., Ichikawa L.E., Barlow W.E., and Ott S.M. Injectable hormone contraception and bone density: results from a prospective study Epidemiol 13 2000 581 587
4. Kaunitz A.M., Miller P.D., Rice V.M., Ross D., and McClung M.R. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation Contraception 74 2006 90 99 (Pubitemid 44096901)
5. Schnatz P.F., Barker K.G., Marakovits K.A., and O'Sullivan D.M. Effects of age at first pregnancy and breast-feeding on the development of postmenopausal osteoporosis Menopause 17 2006 1161 1166
6. World Health Organization WHO statement on hormonal contraception and bone health WHO Epidemiological Record No. 35 2005 World Health Organization Geneva, Switzerland
7. Grimes D.A., and Schulz K.F. Surrogate end points in clinical research: hazardous to your health Obstet Gynecol 105 2005 1114 1118 (Pubitemid 40571032)
8. Grimes D.A., Schulz K.F., and Raymond E.G. Surrogate end points in women's health research: science, protoscience, and pseudoscience Fertil Steril 93 2010 1731 1734
9. Shulman L.P., Bateman L.H., and Creinin M.D. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling Contraception 73 2006 440 442
10. Cundy T., Cornish J., Roberts H., and Reid I.R. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception Am J Obstet Gynecol 186 2002 978 983
11. Orr-Walker B.J., Eveans M.C., Ames R.W., Clearwater J.M., Cundy T., and Reid I.R. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women Clin Endocrinol 49 1998 615 618 (Pubitemid 28529760)
12. Viola A.S., Castro S., Marchi N.M., Bahamondes M.V., Viola C.F.M., and Bahamondes L. Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate Contraception 84 2011 122 127
13. Vestergaard P., Rejnmark L., and Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women Contraception 78 2008 459 464
14. Meier C., Brauchli Y.B., Jick S.S., Kraenzlin M.E., and Meier C.R. Use of depot medroxyprogesterone acetate and fracture risk J Clin Endocrin Metab 95 2010 4909 4916
15. Kaunitz A.M., Harel Z., and Bone H. Retrospective cohort study of DMPA and fractures in reproductive age women Presented at Association of Reproductive Health Professional Annual Meeting, Atlanta, GA. September 24 2010
16. Mosher W.D., and Jones J. Use of contraception in the United States: 1982-2008. National Center for Health Statistics Vital Health Stat 23 29 2010
17. Paschall S., and Kaunitz A.M. Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians Contraception 78 2008 370 376
18. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice ACOG Committee Opinion No. 415: depot medroxyprogesterone acetate and bone effects Obstet Gynecol 112 2008 727 730
19. Cromer B.A., Scholes D., Berenson A., Cundy T., Clark M.K., Kaunitz A.M. Society for Adolescent Medicine Depot medroxyprogesterone acetate and bone mineral density in adolescent - the black box warning: a position paper of the Society for Adolescent Medicine J Adolesc Health 39 2006 296 301 (Pubitemid 44062349)
20. Black A. Canadian contraception consensus: update on depot medroxyprogesterone acetate (DMPA) J Obstet Gynaecol Can 28 2006 305 313
21. Centers for Disease Control Medical eligibility criteria for contraceptive use, 2010 4th ed. Adapted from the WHO medical eligibility criteria for contraceptive use Vol. 59 2010 1 88 MMWR early release May 28